[ad_1]

The Institute of Pharmaceutical Technology (Farmanguinhos/Fiocruz) announced on February 28 a partnership agreement with the Brazilian division of German pharmaceutical company Boehringer Ingelheim, located in Rio de Janeiro. This is the first step in filing and obtaining registration for Jardiance®’s generic products empagliflozin 10 mg and 25 mg with the Brazilian Health Regulatory Agency (Anvisa). This drug is indicated for the treatment of adults with type 2 diabetes to improve blood sugar control. It is also approved by Anvisa to treat patients with heart failure (HF), not only to slow the decline in kidney function, but also to reduce the risk of cardiovascular death and hospitalization for heart failure.

Anvisa’s generic drug approval provides another treatment option for these diseases in SUS (Photo: Viviane Oliveira, Farmanguinhos/Fiocruz)

The approval of generic medicines by Anvisa will enable another treatment option for these diseases in the unified healthcare system (SUS), increasing public access. This partnership aims to collaborate with the development of the Health Economic Industrial Complex (HEIC) and strengthen domestic production of pharmaceuticals to meet the potential demand for SUS.

“This project we are starting today is a roll-out of our huge success against Parkinson’s disease with an innovative drug, and this success is now being rolled out with a new project against neurodegenerative diseases, which “It’s having a huge impact on the field of diabetes and metabolic syndrome,” said Marco Krieger, vice president of health production and innovation at Fiocruz. “We are starting to hit the ground running and the work is now likely to accelerate, but this remains the basis of the process.”

“Boehringer Ingelheim aims to contribute to access to healthcare for the Brazilian people, and this technical cooperation agreement is another important step towards that goal. We are not only expanding our options, but also strengthening the medical economic-industrial complex in Brazil,” commented Andrea Sambati, President of Boehringer Ingelheim Brazil. “Following our successful partnership with Pramipexole, this is another initiative that strengthens our strategic alliance with Farmanginhos/Fiocruz.”

“This agreement strengthens our commitment to SUS to find solutions to health problems affecting Brazilians and to contribute to the domestic production of medicines for the treatment of diabetes and heart failure. For 47 years, we have been supplying generic medicines to the Brazilian people. SUS promotes public health by providing integrated and sustainable solutions,” said Jorge Mendonça, Director of Farmanginhos/Fiocruz. said.

strategic alliance

Our partnership with Boehringer Ingelheim goes back a long way. The agreement signed in November 2011 through the Production Development Partnership (PDP) guaranteed national autonomy in the production of pramipexole dihydrochloride, used to treat Parkinson’s disease. In 2023, Farmanginhos/Fiocruz supplied 16,727,000 drug units (concentrations 0.125 mg, 0.250 mg, 1.0 mg) to SUS, and pramipexole manufactured by the agency was included in Anvisa’s reference drug list.

This partnership aims to cooperate with the development of the medical economic-industrial complex (Photo: Viviane Oliveira, Farmanguinhos/Fiocruz)

Diabetes

A disease caused by insufficient production or malabsorption of insulin, the hormone that regulates glucose in the blood and provides energy for the body. Diabetes and hyperglycemia are associated with increased risk of cardiovascular disease.

According to data from the International Diabetes Federation, 537 million adults (aged 20-79) worldwide live with diabetes (type 1 and type 2). This means that 1 in 10 people are affected by this disease. This number is expected to increase to 643 million in 2030 and 784 million in 2045. Type 2 accounts for approximately 90% of cases worldwide. In Brazil, the number of adults with this disease is 15.7 million, and 73% of patients in the country do not meet their blood sugar goals.

heart failure (HF)

This is a progressive, debilitating, and potentially fatal condition that occurs when the heart does not provide enough blood flow to meet the body’s needs for oxygen and nutrients, or retains fluids to do so. occurs when blood volume increases and fluid builds up in the body (congestion of the lungs and peripheral tissues). Cardiovascular diseases, including heart failure, are the leading cause of mortality and morbidity worldwide. In Brazil, HF is the leading cause of hospitalization for people over 60 years of age.

[ad_2]

Source link